Press Release: Strong second quarter execution drives full year 2022 guidance…

Press Release: Strong second quarter execution drives full year 2022 guidance…


Strong second-quarter execution drives the full-year 2022 guidance update, providing a rich newsflow from research and development in immunology and rare diseases

Paris, July 28, 2022. Read the full press release

Q2 2022 sales growth of 8.1% at CER, driven by Dupixent®rare diseases, vaccines and CHC

  • Specialty Care grew 21.6%, driven by Dupixent® (€1,963 million, +43.4%) and double-digit growth in rare diseases
  • Vaccines rose 8.7% on the strong recovery of travel and booster vaccines as well as continued growth of the PPH franchise
  • General Medicines delivered 6.0% growth in core assets despite lower COVID-19 driven demand for Lovenox®
  • CHC delivered 5th Consecutive growth (+9.1%) driven by cough & cold, allergies and digestive health

Q2 2022 business earnings per share(1) CER up 16.7% driven by higher sales and improved margins

  • BOI margin up 1.3 percentage points to 27.2% on margin improvements from efficiencies and EUROAPI deconsolidation
  • Savings of €2.6 billion achieved at the end of the second quarter, with the majority reinvested in growth drivers and R&D
  • Business EPS(1) of €1.73, up 25.4% on a reported basis and 16.7% over CER
  • IFRS EPS of €0.94 (minus 2.1%)

Progress on corporate social responsibility strategy

  • Sanofi’s Global Health Unit is launching a fund for healthcare solutions in underserved regions and impact®a new brand dedicated to the non-profit distribution of 30 Sanofi products to vulnerable populations in 40 low-income countries
  • Valyou Program continues to improve access through lower cost of insulin for uninsured patients in the US
  • Sanofi has raised its ambition to reduce Scope 3 GHG emissions to -30% by 2030 and unveiled a low-energy-intensity vaccine facility

Key milestones and regulatory achievements in R&D transformation

  • Efanesoctocog alfa, the first factor VIII therapy to receive FDA Breakthrough Therapy Designation for hemophilia A
  • dupixent® Approved in the US as the first-line treatment for adults and children 12 years and older with eosinophilic esophagitis and the first biologic for children 6 months to 5 years of age…


Source story

More to explorer